First Patient Treated in BioInvent's Phase I Study of the Drug Candidate BI-505 to Treat Multiple Myeloma
LUND, Sweden--(BUSINESS WIRE)--BioInvent International AB (STO:BINV) announced today that the first patient has been treated in an open, dose-escalation phase I study of the company’s antibody BI-505 for patients with advanced multiple myeloma.